Researchers presented 10-year cardiovascular disease (CVD) risk and low-density lipoprotein cholesterol (LDL-C) reduction calculations for alirocumab and evolocumab. WASHINGTON, DC—At the ACC.17 ...
Studies on PCSK9 inhibitors, evolocumab and alirocumab, promote new guidelines for dyslipidemia management through lipid modification to reduce cardiovascular risk. New European Society of Cardiology ...
The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...
On Friday, for the first time, we saw the full data from the FOURIER clinical trial of Amgen’s cholesterol-lowering antibody, evolocumab (Repatha). Depending on who you listen to, it was either “the ...
WASHINGTON, DC (UPDATED)—The eagerly anticipated final results of FOURIER, a large clinical trial testing evolocumab (Repatha, Amgen) in patients with stable atherosclerotic cardiovascular disease, ...
PubMed and Scopus databases were searched to retrieve clinical trials on the efficacy and/or safety of novel LDL-C-lowering agents including PCSK9 inhibitors, mipomersen (Kynmaro®), lomitapide ...
One of the priciest cardiovascular medicines will soon be available at a much lower cost. Amgen announced yesterday they have reduced the list price of evolocumab (Repatha) by 60%, cutting the cost of ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Reducing LDL to very low levels with the PCSK9 inhibitor alirocumab lowered risk for major ...
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results